Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Moderna jumps as personalized cancer vaccine shows benefit in early study
11:26am, Tuesday, 09'th Apr 2024
Moderna shares rose 8% in morning trade on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of he
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
04:50am, Tuesday, 09'th Apr 2024
These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
02:35pm, Friday, 05'th Apr 2024
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
01:54pm, Friday, 05'th Apr 2024
With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. Fo
Moderna shares fall after judge sides with Arbutus in patent fight
02:02pm, Wednesday, 03'rd Apr 2024
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Tuesday, 02'nd Apr 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Moderna (MRNA) Dipped More Than Broader Market Today
06:56pm, Monday, 01'st Apr 2024
Moderna (MRNA) reachead $105.60 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.
Moderna Stock: Buy, Sell, or Hold?
08:45am, Monday, 01'st Apr 2024
Moderna has proven that its approach can work, making an investment less risky. In addition to its COVID-19 vaccine, the company is developing other products.
Better Recovery Story Buy: Pfizer vs Moderna
05:05am, Monday, 01'st Apr 2024
Pfizer and Moderna, both coronavirus vaccine stars, now face declining demand -- and, as a result, declining revenue. But these top companies are expanding their growth potential with new candidates t
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
12:41pm, Thursday, 28'th Mar 2024
Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
Three top U.S. biotech stocks to buy in April
09:06am, Thursday, 28'th Mar 2024
“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
08:39am, Thursday, 28'th Mar 2024
Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.
Better Cathie Wood Stock: Moderna vs. Intellia
05:55am, Thursday, 28'th Mar 2024
Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.
Moderna CEO talks China investment, vaccine updates to boost growth post-pandemic
04:46pm, Wednesday, 27'th Mar 2024
Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-ov
Moderna Stock Pops After Acquiring Millions in Funding
02:29pm, Wednesday, 27'th Mar 2024
Moderna Inc (NASDAQ:MRNA) is 1.8% higher to trade at $109.29 at last check, after the company received $750 million in funding from Blackstone Life Sciences (BX) to develop mRNA flu vaccines.
